Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Breyanzi
Pharma
Gilead reports 7% sales decline for CAR-Ts Yescarta, Tecartus
Gilead reported that sales of its cell therapies were down 7%, with blockbuster Yescarta declining by 5%.
Kevin Dunleavy
Aug 8, 2025 11:40am
FDA removes barrier to CAR-Ts; move likely to boost uptake
Jun 27, 2025 11:14am
BMS calls it quits on vector production at former Novartis plant
May 2, 2025 11:20am
BMS angles Breyanzi for another blood cancer
Feb 10, 2025 9:50am
Pfizer, BMS and more start 2025 with drug price hikes: report
Jan 2, 2025 10:42am
FDA revisits CAR-T boxed warning on secondary cancers: Marks
Nov 1, 2024 10:30am
